BIO-TECHNE Corp vs Zillow Group Inc Class A — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Zillow Group Inc Class A trades at $29.88 (market cap $6.17B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Zillow Group Inc Class A for 87 Days on average.
| TECH | ZG | |
|---|---|---|
Market Cap | $11.37B | $6.17B |
Volume | 3,153,511 | 1,297,576 |
Sector | Health | Media |
52-Week High | $72.61 | $74.58 |
52-Week Low | $43.31 | $27.70 |
Typical Hold Time | 63 Days | 87 Days |
Enterprise Value | $11.40B | $6.04B |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Zillow Group (ZG) trades at $29.90, up 5.43% over 24 hours, with technical indicators showing a bearish trend but oscillators neutral. The company reported a return to profitability in 2025 with net income of $23 million, reversing prior losses, and revenue growth to $2.58 billion. Recent earnings have mostly beaten expectations, with Q1 and Q2 2026 exceeding estimates. Cash flow from operations remains positive, though net cash flow was negative $312 million in 2025. Analyst sentiment is mixed with a consensus price target of $48.87, suggesting significant upside from current levels.
ZG's outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but faces risks from a challenging housing market and high valuation multiples. The stock offers potential for appreciation if execution continues, but investors should weigh competitive pressures and macroeconomic headwinds against the positive analyst targets and recent institutional interest.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →